AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06275347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Balanced Diet
Description: Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
Study NCT06057844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional blood sampling
Description: Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
Study NCT06480305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Breakfast-3
Description: Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.
Study NCT05593939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
Study NCT05593939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
Study NCT05593939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
Study NCT04984330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
Study NCT04984330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
Study NCT04929574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram and Hematological Analysis
Description: Echocardiogram and Hematological Analysis
Study NCT05561569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: 23 gauge pars plana vitrectomy for managing primary retinal detachment.
Study NCT06360029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP
Description: The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant.
Study NCT06360029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP + MI
Description: After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle).
Study NCT06360029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
Study NCT05546242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir/Rilpivirine
Description: injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
Study NCT05546242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral
Description: Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
Study NCT04667481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: Participate in aerobic exercise intervention
Study NCT04667481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Intervention
Description: Participate in resistance exercise intervention
Study NCT04667481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention: Digital copies and outline of sessions
Description: Receive digital copy of AE and RE sessions and an outline of sessions
Study NCT04667481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04667481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06166589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
Study NCT06166589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
Study NCT06166589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA > 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
Study NCT06166589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
Study NCT06225999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection (S095013)
Description: Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study NCT06225999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study NCT06225999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LLV (levoisomer form of leucovorin)
Description: LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study NCT06225999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5- FU (5-Fluorouracil)
Description: 5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Study NCT06553807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.
Description: The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
Study NCT06555471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg iv q3w d1
Study NCT06555471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；>1.8m2 60mg/time)
Study NCT06555471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
Study NCT06555471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extraperitoneal radiation therapy
Description: once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
Study NCT05674370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRIP Electronic Diagnostic Chip
Description: Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
Study NCT05674370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory-based nucleic acid amplification tests (NAATs)
Description: Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
Study NCT05463354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection
Study NCT05463354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection
Study NCT05291910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
Study NCT05291910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT05353036 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey assessing incidence, frequency, and type of illicit substance use
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin for Injection
Description: 1.8mg/kg/dose (MAX 180 mg)
Study NCT05291910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 130mg/m2, IV , D1, D8, q3w
Study NCT06163157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage(CTM)
Description: CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
Study NCT06001255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study NCT04619602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSNO
Description: Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
Study NCT06641011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (resin- based) after blot-drying silver fluoride application
Description: Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant
Study NCT06641011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (GI- based) after blot-drying silver fluoride application
Description: Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant
Study NCT06641011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (Resin based) after rinsing silver fluoride application
Description: Rinsing silver fluoride off followed by resin-based fissure sealant
Study NCT06641011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate restoration (GIC) after rinsing silver fluoride application
Description: Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant
Study NCT06641011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin based fissure sealant restoration one week after silver fluoride (AgF) application
Description: Resin based fissure sealant restoration one week after silver fluoride (AgF) application
Study NCT06641011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GI- based fissure sealant restoration one week after silver fluoride (AgF) application
Description: GI- based fissure sealant restoration one week after silver fluoride (AgF) application
Study NCT06216288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated back extension exercise (McKenzie)
Description: repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
Study NCT04750512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
Study NCT05453955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
Study NCT05453955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Study NCT06216288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated back extension exercise (McKenzie)
Description: repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
Study NCT04697576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: immune checkpoint inhibitor
Study NCT06563245 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: response-adapted radiation
Description: For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
Study NCT04697576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: immune checkpoint inhibitor
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25mg/m2/dose,
Study NCT06563245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 125 mg/m2/dose
Study NCT06216288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical traction
Description: The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
Study NCT04750512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle.
Study NCT06400082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
Study NCT06400082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
Study NCT05298930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges.
Study NCT06638411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHD information workshop
Description: ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.
Study NCT06638411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHD information workshop with nocebo education
Description: ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.
Study NCT06638411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep workshop
Description: An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
Study NCT05851963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonicare Diamond Clean 9000
Description: Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
Study NCT05851963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HydroSonic Pro
Description: Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
Study NCT05851963 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Oral-B 123
Description: Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
Study NCT05851963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curaprox CS 5460
Description: Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
Study NCT04961593 — intervention group
Intervention type: DRUG
Intervention: Caspofungin
Description: For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.